Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
1995
Strolin Benedetti M., Tocchetti P., Rocchetti M., Martignoni M., Marrari P., Poggesi I. and Doster P.
Enatioselective Recognition of Two Anticonvultants, FCE 26743 and FCE 28073 by MAO, and Relationship Between MAO-B Inhibition and FCE 26743 Concentrations in Rat Brain.
Progress in Brain Res., 106: 123-134, 1995